Search

everythinglearnresearchcommunity

for

Search:↓

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.

The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.

Bimatoprost is preferred over Latanoprost for hair growth. Users are seeking a reliable supplier for raw Bimatoprost powder to make their own topical solution.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The conversation is about purchasing dutasteride solution for mesotherapy, with a suggestion to make it using dutasteride capsules and oils. A user shared a link to a potential supplier and mentioned using dutasteride with microneedling.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.

The conversation discusses hair loss treatments beyond the commonly known three, focusing on separating effective treatments from myths. Dutasteride and low-dose oral Minoxidil are mentioned as having clinical evidence for increasing hair counts, but with potential side effects.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

The conversation discusses the pros and cons of dutasteride for male pattern baldness, with a focus on its long half-life. The user, a physician, also mentions that switching from finasteride to dutasteride can cause temporary hair loss until dutasteride reaches effective levels or accelerates the hair cycle.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation discusses using GHK-Cu, C60, and saw palmetto oil as treatments for hair loss. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).

The conversation discusses using aromatase inhibiting supplements like DIM and Grape Seed extract while on finasteride for hair loss treatment. Users share their experiences and opinions on combining these supplements with finasteride.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

Dutasteride and Minoxidil are not effectively preventing hair loss. Supplementing with Vitamin D and B12 is recommended.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

The user is using RU58841 twice daily, dutasteride 0.5mg every two days, dutasteride mesotherapy every three months, and 20mg oral minoxidil daily. Other users suggest this regimen is excessive and recommend adding microneedling and ketoconazole shampoo.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The user has accepted their hair loss and uses finasteride and minoxidil, with past use of RU58841 and dutasteride. They seek advice on supplements to slow down graying hair.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.